Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends

SIMPLE SUMMARY: Therapeutic advances in the treatment of HER2-positive metastatic breast cancer have dramatically improved the natural history of these patients. Although double anti-HER2 blockade associated with a taxane currently remains the best option in the first line, recently, T-DXd has posit...

Descripción completa

Detalles Bibliográficos
Autores principales: Vega Cano, Kreina Sharela, Marmolejo Castañeda, David Humberto, Escrivá-de-Romaní, Santiago, Saura, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817525/
https://www.ncbi.nlm.nih.gov/pubmed/36612047
http://dx.doi.org/10.3390/cancers15010051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817525/
https://www.ncbi.nlm.nih.gov/pubmed/36612047
http://dx.doi.org/10.3390/cancers15010051

Ejemplares similares